Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $6.6 million.

  • Crinetics Pharmaceuticals' Change in Accured Expenses rose 86613.37% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 14707.69%. This contributed to the annual value of $17.5 million for FY2024, which is 1975.01% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $6.6 million for Q3 2025, which was up 86613.37% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Change in Accured Expenses ranged from a high of $12.5 million in Q2 2025 and a low of -$1.4 million during Q1 2025
  • For the 5-year period, Crinetics Pharmaceuticals' Change in Accured Expenses averaged around $3.5 million, with its median value being $3.9 million (2021).
  • In the last 5 years, Crinetics Pharmaceuticals' Change in Accured Expenses crashed by 36923.08% in 2022 and then surged by 86613.37% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $3.9 million in 2021, then grew by 4.75% to $4.1 million in 2022, then rose by 2.65% to $4.2 million in 2023, then surged by 146.72% to $10.3 million in 2024, then crashed by 35.72% to $6.6 million in 2025.
  • Its Change in Accured Expenses was $6.6 million in Q3 2025, compared to $12.5 million in Q2 2025 and -$1.4 million in Q1 2025.